Clinical Trial

TDM-optimized Teicoplanin Dosing Versus Standard of Care

Study acronym: PLATO-3
Terminated Phase 4
View on ClinicalTrials.gov →
Why the trial stopped
The intervention was deemed futile the intervention group, as TDM was not needed in patients with a 12mg/kg dose. In consultation with the METC and biostatistics it was decided to terminate the study early.
Summary
Value of TDM for teicoplanin is not well defined. In this single-center low-interventional randomized trial the investigators aim to investigate the superiority of teicoplanin TDM-optimized using Model-Informed-Precision-Dosing (MIPD) of unbound concentrations versus the standard of care (dosing based on antibiotic guidelines) in target attainment.
Protocol Amendment History 5 changes
critical Trial terminated 2026-08-13
critical Trial terminated: The intervention was deemed futile the intervention group, as TDM was not needed in patients with a 12mg/kg dose. In co... 2026-08-13
notable Enrollment reduced: 74 -> 54 participants 2026-08-13
notable Primary completion moved earlier: 2026-04-30 -> 2026-02-20 2026-08-13
minor Completion moved earlier: 2026-04-30 -> 2026-02-20 2026-08-13
Trial Details
NCT Number NCT05914467
Lead Sponsor Radboud University Medical Center
Collaborators: ZonMw: The Netherlands Organisation for Health Research and Development
Conditions Bacterial Infections
Enrollment 54 participants
Start Date 2023-08-01
Primary Completion 2026-02-20 (estimated)
Study Completion 2026-02-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-12